This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
The Zacks Analyst Blog Highlights Boston Scientific, Hologic, BioTechne, STERIS and Align
by Zacks Equity Research
Boston Scientific, Hologic, BioTechne, STERIS and Align are included in this Analyst Blog.
Can These 5 MedTech Stocks Hit Earnings Targets This Season?
by Urmimala Biswas
Here is a sneak peek into how five MedTech stocks, BSX, HOLX, TECH, STE and ALGN, are expected to fare in their quarterly results, slated to be released tomorrow.
Align Technology (ALGN) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Align Technology (ALGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Labcorp (LH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LH or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LH vs. ALGN: Which Stock Is the Better Value Option?
Align Technology (ALGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALGN Gears Up for Q4 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Align Technology's fourth-quarter results are likely to reflect the strength in its Systems & Services business.
Why Align Technology (ALGN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Align Technology (ALGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Align Technology Shares Hurt by Macro Issues, Decline in ASPs
by Zacks Equity Research
ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This resulted in a decline in the company's revenues.
Zacks Investment Ideas feature highlights: Align Technology and Coca-Cola
by Zacks Equity Research
Align Technology and Coca-Cola are part of the Zacks Investment Ideas article.
2 Strong Stocks to Buy Now While They're Still on Sale
by Benjamin Rains
Two stocks (ALGN and KO) to buy in January trading at least 20% below their average Zacks price targets that also offer great long-term value.
CNMD vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
CNMD vs. ALGN: Which Stock Is the Better Value Option?
5 MedTech Stocks That Are Poised to Beat the Market in 2025
by Harshit Gupta
Here, we discuss five stocks that are likely to generate better than the market, driven by strong demand for existing products and the addition of innovative new devices.
Should You Hold Align Technology Stock in Your Portfolio Right Now?
by Zacks Equity Research
ALGN stock stays on investors' radar, courtesy of its strong Invisalign potential and success with iTero.
Align Shares Down on Macroeconomic Issues, ASP Challenges
by Zacks Equity Research
ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This results in a decline in the company's revenues.
Is the Options Market Predicting a Spike in Align Technology (ALGN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Align Technology (ALGN) stock based on the movements in the options market lately.
Why Is Align Technology (ALGN) Up 5.5% Since Last Earnings Report?
by Zacks Equity Research
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ALGN Stock to Gain From CE Mark Win for Invisalign Palatal Expander
by Zacks Equity Research
Align Technology achieves a CE mark for the Invisalign Palatal Expander System.
Boot Barn and Align Technology have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Boot Barn and Align Technology are part of the Zacks Bull and Bear of the Day article.
Bear of the Day: Align Technology (ALGN)
by Jeremy Mullin
Will this stock find the right alignment to avoid further decline?
ALGN Stock Rise on the Release of Invisalign Smile Architect Software
by Zacks Equity Research
Align Technology unveils Invisalign Smile Architect software with Multiple Treatment Plans for providing customised treatment.
ALGN Q3 Earnings Top Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
Align Technology reports third-quarter 2024 revenue growth. This can be mostly attributed to a robust performance by the Imaging Systems & CAD/CAM Services business segment.
Align Technology (ALGN) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Align Technology (ALGN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Align Technology (ALGN) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 1.73% and 1.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?